

## World Congress on SKIN CARE, DERMATOLOGY AND ALLERGIC DISEASES

September 06, 2021 | Webinar

**Dupilumab induced facial erythema: superior effect of topical antifungal in comparison to oral****Amnah Almulhim, Yasir Shaikh, Lenah Shaikh, Ahad Shaikh***King Fahad Specialist Hospital, Saudi Arabia*

Atopic dermatitis (AD) is a common disease that affects different age groups ranging from mild to severe. For a patient with severe atopic dermatitis, systemic treatment options are limited, the first biological medication approved for the treatment of AD is dupilumab. Dupilumab was initially approved by the food and drug administration (FDA) for the treatment of adults with AD followed by adolescents and recently approved for the treatment of pediatrics with AD. Like other approved medication some side effects are not reported before the phase III trial. Thereby we present a case of dupilumab induced facial erythema treated with oral and topical antifungal. We believe the incidence of facial erythema in patients taking dupilumab is low, however it is still encounterable with limited described data. Our patient responded to topical antifungal better than oral, thus we recommend a trial of topical treatment as a first line for dupilumab induced facial erythema.

**Biography**

Amnah Almulhim is dermatology assistant consultant with humble experience in evaluating and managing dermatological diseases. She presented this case after successfully treating observed side effect. Her recommended treatment option is described due to the lack of treatment consensus for such encounter. Treatment needs to be tried on more patients to have definitive result.

amna.almulhim@gmail.com